中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2015年
10期
41-43
,共3页
非小细胞肺癌%化疗%铂剂
非小細胞肺癌%化療%鉑劑
비소세포폐암%화료%박제
Non-small cell lung cancer%Chemotherapy%Platinum agent
目的 探讨不同含铂治疗方案在晚期非小细胞肺癌患者中的应用效果.方法 选择2011年3月至2012年9月许昌市中心医院收治的非小细胞肺癌的初治患者220例,根据化疗方案的不同分为紫杉醇组、吉西他滨组和多西他赛组.分别对其疗效及不良反应进行评价.结果 三组患者采用不同的治疗方案治疗后的ORR以及DCR比较差异均未见统计学意义(P＞0.05).随访至2014年4月,有107例患者由于随访后期未定期进行影像学检查导致无法对疾病进展情况进行有效评估,余113例评定无进展生存期发现,吉西他滨组的无进展生存期最优,紫杉醇组次之,多西他赛组相对较差;紫杉醇组神经毒性明显重于多西他赛组,吉西他滨组最小,差异有统计学意义(P＜0.05).结论 三种不同含铂治疗方案治疗晚期非小细胞肺癌均具有较好的疗效,但相比而言,紫杉醇与吉西他滨方案更能够延缓病情进展,近期疗效曼佳,而吉西他滨的安全性更好.
目的 探討不同含鉑治療方案在晚期非小細胞肺癌患者中的應用效果.方法 選擇2011年3月至2012年9月許昌市中心醫院收治的非小細胞肺癌的初治患者220例,根據化療方案的不同分為紫杉醇組、吉西他濱組和多西他賽組.分彆對其療效及不良反應進行評價.結果 三組患者採用不同的治療方案治療後的ORR以及DCR比較差異均未見統計學意義(P＞0.05).隨訪至2014年4月,有107例患者由于隨訪後期未定期進行影像學檢查導緻無法對疾病進展情況進行有效評估,餘113例評定無進展生存期髮現,吉西他濱組的無進展生存期最優,紫杉醇組次之,多西他賽組相對較差;紫杉醇組神經毒性明顯重于多西他賽組,吉西他濱組最小,差異有統計學意義(P＜0.05).結論 三種不同含鉑治療方案治療晚期非小細胞肺癌均具有較好的療效,但相比而言,紫杉醇與吉西他濱方案更能夠延緩病情進展,近期療效曼佳,而吉西他濱的安全性更好.
목적 탐토불동함박치료방안재만기비소세포폐암환자중적응용효과.방법 선택2011년3월지2012년9월허창시중심의원수치적비소세포폐암적초치환자220례,근거화료방안적불동분위자삼순조、길서타빈조화다서타새조.분별대기료효급불량반응진행평개.결과 삼조환자채용불동적치료방안치료후적ORR이급DCR비교차이균미견통계학의의(P＞0.05).수방지2014년4월,유107례환자유우수방후기미정기진행영상학검사도치무법대질병진전정황진행유효평고,여113례평정무진전생존기발현,길서타빈조적무진전생존기최우,자삼순조차지,다서타새조상대교차;자삼순조신경독성명현중우다서타새조,길서타빈조최소,차이유통계학의의(P＜0.05).결론 삼충불동함박치료방안치료만기비소세포폐암균구유교호적료효,단상비이언,자삼순여길서타빈방안경능구연완병정진전,근기료효만가,이길서타빈적안전성경호.
Objective To investigate the effect of different applications on advanced platinumcontaining regimen in patients with non-small cells lung cancer.Methods Two hundred and twenty patients with non-small cell lung cancer were retrospectively selected from March 2011 to September 2012 in the Central Hospital of Xuchang,according to different chemotherapy,all the patients were divided into paclitaxel,gemcitabine and docetaxel group.The efficacy and adverse reactions were evaluated.Results The sex,age,pathological type,stage and the classification of the platinum agent of the three groups of patients were compared,there was no statistically significant difference (P ＞ 0.05).Three groups of patients with different treatment regimen,there were no statistically significant difference in ORR or DCR (P ＞ 0.05).Followed up to April 2014,107 patients unable to be evaluated due to late follow-up without imaging examination on a regular basis,an effective evaluation of the progress of the disease,the progression-free survival,in gemcitabine group was optimal,taxol group took second place,docetaxel group was relatively poor.The neurotoxicity of taxol group was significantly heavier than that of docetaxel group,gemcitabine group neurotoxicity was minimum.The difference were statistically significant (P ＜ 0.05).Conclusions Three different platinum-based treatment of advanced non-small cell lung cancer treatment has good effect,but paclitaxel and gemcitabine program is able to slow down the disease progression,the short-term curative effect is better,and the security of gemcitabine is better.
